Skip to main content
Erschienen in: BMC Cancer 1/2019

Open Access 01.12.2019 | Research article

Prognostic value of lymphovascular invasion in patients with squamous cell carcinoma of the penis following surgery

verfasst von: Kai Li, Jian Sun, Xuedong Wei, Guang Wu, Fei Wang, Caibin Fan, Hexing Yuan

Erschienen in: BMC Cancer | Ausgabe 1/2019

Abstract

Background

To evaluate the prognostic value of Lymphovascular Invasion (LVI) in patients with squamous cell carcinoma of the penis (SCCP) following surgery.

Patients and methods

This retrospective study analyzed the data of 891 eligible patients with SCCP who were diagnosed between 2010 and 2014, obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were categorized by LVI, age, grade, T stage, lymph nodes status, distant metastasis, regional lymph nodes removed, and surgery. Overall survival (OS) and penile carcinoma-specific survival (PCSS) were evaluated by Kaplan-Meier method and Cox proportional hazards regression model.

Results

The presence of LVI was significantly associated with increased risk of advanced T stage, high grade, lymph node metastasis, and distant metastasis (P < 0.001 for all). In Kaplan-Meier analyses, patients with the presence of LVI had significantly lower OS and PCSS than those with the absence of LVI (P < 0.001 for both,). The presence of LVI was also significantly associated with poorer OS and worse PCSS in patients with Tx + Ta + T1 stage (P = 0.007, P < 0.001), N0 stage (P < 0.001, P = 0.040), grade 1 (P = 0.001, P < 0.001), grade 2 (P = 0.001, P = 0.014), no distant metastasis (P < 0.001 for both), no regional lymph nodes removed (P < 0.001 for both), Non-radical surgery (P < 0.001 for both) and radical surgery(P = 0.037, P = 0.002). In multivariate analyses, the presence of LVI in patients with SCCP following surgery was found to be a significant independent predictor of decreased OS (hazard ratio 1.403, P = 0.039).

Conclusions

The LVI status might be a crucial prognostic indicator for overall survival in patients with SCCP.
Hinweise
Kai Li and Jian Sun contributed equally to this work.
Abkürzungen
AJCC
American Joint Committee on Cancer
CI
Confidence intervals
HR
Hazard ratio
LVI
Lymphovascular Invasion
OS
Overall survival
PCSS
Penile carcinoma-specific survival
SCCP
Squamous cell carcinoma of the penis
SEER
The Surveillance, Epidemiology, and End Results database

Background

Penile carcinoma is a rare malignant disease, with an estimated annual incidence of 2–4 cases per 100,000 men in the developing countries of Africa, Asia, and South America; however, it is significantly rarer in the United States and Europe (0.3–1 cases per 100,000 males) [1]. The squamous cell carcinoma of the penis (SCCP) represents over 95% of penile carcinomas and is the most common type [2, 3]. It most commonly occurs at an advanced age; with the peak age of presentation is between 50 and 70 years [3]. Organ preservation strategy is a preferred treatment modality for early stage penile carcinoma; however, surgical resection with a partial or radical penectomy remains the oncological gold standard therapy for advanced invasive penile carcinoma [4].
Lymphovascular invasion (LVI) is described as the presence of tumor cell invasion into blood vessels or the lymphatic system [5]. LVI is a primary and crucial phase in the systemic metastasis of cancer cells [6]. Increasing evidence suggests that the presence of LVI is a poor prognostic indicator in various types of malignancies, including bladder cancer [7], prostate cancer [8], clear cell renal cell carcinoma [9], esophageal cancer [10], breast cancer [5] and lung cancer [11]. Presently, there are only limited studies on the association of LVI with the clinical outcome of patients with penile carcinoma. Recently, evidence showed that the presence of LVI was a significant risk factor for occult micrometastases in patients with penile carcinoma [12]. Moreover, previous studies suggested that lymphovascular embolization was a significant risk factor for increased lymphatic metastasis in patients with penile carcinoma [13]. However, current indication remains elusive. Furthermore, LVI is not considered in guidelines for treatment strategies for penile carcinoma, due to the paucity of adequate data to substantiate the effects of LVI on clinicopathological characteristics and survival outcome. Therefore, the present study aimed to evaluate the association of LVI with clinicopathological characteristics. Further, the impact of LVI on survival outcome of men with SCCP was also investigated.

Patients and methods

This retrospective study analyzed the data of 891 eligible patients with penile SCCP diagnosed and underwent surgery between 2010 and 2014, obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The database accession number is 13638-Nov2017. According to the “International Classification of Diseases-Oncology, 3rd edition” (ICD-O-3), tumors with codes 8051–8052 and 8070–8075 were classified as pure squamous cell carcinoma [14]. However, cases with incomplete records on LVI, grade, regional lymph nodes removed, and surgery were excluded from the study.
Demographic characteristics of patients including age (< 50 and ≥ 50 years old) and clinicopathological characteristics including LVI, T stage, grade (grade I- IV), lymph nodes status, distant metastasis, regional lymph nodes removed, and surgery (radical surgery and Non-radical surgery) were collected. TNM stages of the penile tumor were determined according to the American Joint Committee on Cancer (AJCC) 7th edition staging system using available clinical and pathologic data on tumor invasion, lymph nodes status, and distant metastasis, respectively. The histopathological grading of penile carcinoma was determined according to the Broder’s classification system [15]. All the specimens were subjected for routine histopathologic examination.
For survival outcome, overall survival (OS) was defined as a time period between the date of SCCP diagnosis and the date of death or last follow-up. Penile carcinoma-specific survival (PCSS), a time period from the date of SCCP diagnosis to the date of carcinoma-specific death or censoring was also determined. The cause of death was obtained from the death certificate. All patients with SCCP were followed up until December 31, 2014, in this study, with a median follow-up period of 16 months (range, 0 to 59).
All statistical analyses were performed using SPSS version 17.0 software (IBM, Chicago, IL, USA). A two-tailed chi-square test was used to determine the significance of differences between categorical variables. The Kaplan-Meier method was used to calculate survival functions, and differences were assessed using the log-rank statistic. Univariate and multivariate analyses were performed using backward stepwise Cox proportional hazards regression model to determine potential prognostic factors for OS and PCSS. Besides, adjusted hazard ratio (HR) and 95% confidence intervals (CI) were used to express the magnitudes of statistical significance in the model. All reported p-values were two-sided, and a p-value of < 0.05 was considered statistically significant.

Results

A total of 891 eligible patients with SCCP were included in this study. The presence of LVI was detected in 186 patients (20.9%), and 705 patients (79.1%) had SCCP without LVI. The median follow-up time was 16 months (range, 0 to 59). A total of 235 (26.4%) patients with SCCP died during this study. Of the 235 deaths, 91 patients died from SCCP.
The association of LVI with demographic characteristics and clinicopathological characteristics were presented in Table 1. The presence of LVI significantly increased the risk of advanced T stage, high grade, lymph node metastasis, and distant metastasis (P < 0.001 for all). However, there was no statistically significant difference in age between the patients with LVI and those without LVI (P = 0.125). Besides, patients who removed regional lymph nodes exhibited a lower incidence of SCCP with LVI than those who did not remove regional lymph nodes (P < 0.001). Similarly, patients who received radical surgery showed a lower incidence of SCCP with LVI compared to those who did not (P = 0.004).
Table 1
Association of LVI with clinicopathological characteristics
N(%) variables
All patients
LVI absent
LVI present
P
No. of Patients
891
705(79.1)
186(20.9)
 
Age
   
0.125
  < 50
100(11.2)
85(85.0)
15(15.0)
  ≥ 50
791(88.8)
620(78.4)
171(21.6)
T stage
   
< 0.001
 Tx + Ta + T1
457(51.3)
416(91.0)
41(9.0)
 T2
242(27.2)
186(76.9)
56(23.1)
 T3
178(20.0)
94(52.8)
84(47.2)
 T4
14(1.6)
9(64.3)
5(35.7)
Lymph nodes status
   
< 0.001
 Nx
21(2.4)
13(61.9)
8(38.1)
 N0
704(79.0)
595(84.5)
109(15.5)
 N1-N3
166(18.6)
97(58.4)
69(41.6)
Grade
   
< 0.001
 G1
242(27.2)
222(91.7)
20(8.3)
 G2
462(51.9)
372(80.5)
90(19.5)
 G3 + G4
187(21.0)
111(59.4)
76(40.6)
Distant metastasis
   
< 0.001
 No
864(97.0)
691(80.0)
173(20.0)
 Yes
27(3.0)
14(51.9)
13(48.1)
Regional lymph nodes removed
   
< 0.001
 No
683(76.7)
572(83.7)
111(16.3)
 Yes
208(23.3)
133(63.9)
75(36.1)
Surgery
   
0.004
 Non-radical surgery
853(95.7)
682(80.0)
171(20.0)
 Radical surgery
38(4.3)
23(60.5)
15(39.5)
LVI lymphovascular invasion; SCCP squamous cell carcinoma of the penis
Significant values in bold
In Kaplan-Meier analyses, patients with the presence of LVI had significantly lower OS and PCSS than those with the absence of LVI (P < 0.001 for both, Table 2 and Fig. 1). The presence of LVI was also significantly associated with poorer OS and worse PCSS in patients with Tx + Ta + T1 stage (P = 0.007, P < 0.001, Table 2 and Fig. 2), N0 stage (P < 0.001, P = 0.040, Table 2 and Fig. 3), grade 1 (P = 0.001, P < 0.001, Table 2 and Fig. 4), grade 2 (P = 0.001, P = 0.014, Table 2 and Fig. 4), no distant metastasis (P < 0.001 for both, Table 2 and Fig. 5), no regional lymph nodes removed (P < 0.001 for both, Table 2 and Fig. 6), Non-radical surgery (P < 0.001 for both, Table 2 and Fig. 7) and radical surgery(P = 0.037, P = 0.002, Table 2 and Fig. 7). Moreover, the presence of LVI was significantly associated with poorer OS in patients with T2 stage (P = 0.011, Table 2 and Fig. 2) and regional lymph nodes removed (P = 0.016, Table 2 and Fig. 6). The 3-year survival was shown in Table 2.
Table 2
Overall survival and penis cancer-specific survival estimates with clinicopathological characteristics according to LVI
 
Overall survival,%
Penile carcinoma-specific survival,%
Group
3-Year Probability (SEM)
P
3-Year Probability (SEM)
P
All patients
 
< 0.001
 
< 0.001
LVI absent
68.1(2.3)
 
85.3(1.9)
LVI present
48.6(4.6)
 
68.5(4.8)
T stage
 Tx + Ta + T1
 
0.007
 
< 0.001
 LVI absent
73.3(2.9)
 
90.7(2.0)
 LVI present
53.7(9.6)
 
65.4(10.3)
 T2
 
0.011
 
0.163
 LVI absent
66.3(4.5)
 
80.4(4.5)
 LVI present
42.1(8.8)
 
75.4(8.3)
 T3
 
0.368
 
0.584
 LVI absent
48.0(7.2)
 
69.9(7.0)
 LVI present
54.1(6.4)
 
69.0(7.0)
 T4
 
0.067
 
0.207
 LVI absent
66.7(20.8)
 
85.7(11.7)
LVI present
 
Lymph nodes status
 Nx
 
0.826
 
0.515
 LVI absent
44.5(17.7)
 
88.9(10.5)
 LVI present
57.1(18.7)
 
66.7(19.2)
 N0
 
< 0.001
 
0.040
 LVI absent
72.9(2.4)
 
91.0(1.7)
 LVI present
56.7(6.0)
 
84.3(5.0)
 N1-N3
 
0.145
 
0.227
 LVI absent
44.4(6.5)
 
54.7(7.2)
 LVI present
35.9(7.5)
 
48.1(8.6)
Grade
 G1
 
0.001
 
< 0.001
 LVI absent
76.4(3.7)
 
97.1(1.4)
 LVI present
45.0(12.7)
 
50.9(14.8)
 G2
 
0.001
 
0.014
 LVI absent
67.0(3.2)
 
81.1(3.0)
 LVI present
49.5(6.6)
 
70.6(6.8)
 G3 + G4
 
0.181
 
0.408
 LVI absent
54.7(6.4)
 
75.8(5.7)
 LVI present
47.3(7.8)
 
70.9(7.7)
Distant metastasis
 No
 
< 0.001
 
< 0.001
 LVI absent
69.6(2.3)
 
87.2(1.9)
 LVI present
49.9(4.8)
 
70.8(4.9)
 Yes
 
0.286
 
0.208
LVI absent
 
LVI present
35.6(15.6)
 
45.5(17.6)
Regional lymph nodes removed
 No
 
< 0.001
 
< 0.001
 LVI absent
68.3(2.5)
 
88.6(1.9)
 LVI present
45.6(5.9)
 
67.6(6.7)
 Yes
 
0.016
 
0.137
 LVI absent
67.9(5.4)
 
74.6(5.2)
 LVI present
53.3(7.4)
 
69.9(6.9)
Surgery
 Non-radical surgery
 
< 0.001
 
< 0.001
 LVI absent
68.7(2.3)
 
85.4(2.0)
 LVI present
52.0(4.8)
 
72.1(4.9)
 Radical surgery
 
0.037
 
0.002
 LVI absent
50.8(16.5)
 
87.1(8.6)
 LVI present
13.7(11.8)
 
26.7(15.6)
LVI lymphovascular invasion; SCCP squamous cell carcinoma of the penis; SEM standard error of mean
Significant values in bold, “-” = no data
The associations of clinicopathological variables with OS and PCSS are shown in Table 3. Univariate analyses found that LVI, grade, T stage, lymph nodes status, distant metastasis, regional lymph nodes removed, and surgery were significantly associated with OS and PCSS. Furthermore, although the results showed that regional lymph nodes removed, which played an important role in the treatment of penile cancer, wasn’t associated with OS (P = 0.690), we also included it in multivariate analyses.
Table 3
Univariate analyses of overall survival and penis cancer-specific survival
Variables
Overall survival
Penile carcinoma-specific survival
Hazard Ratio
95% CI
P
Hazard Ratio
95% CI
P
Age
1.556
0.962–2.517
0.071
0.796
0.450–1.407
0.432
T stage
  
< 0.001
  
< 0.001
Tx + Ta + T1
 
Referent
 
Referent
T2
1.543
1.134–2.100
0.006
1.827
1.086–3.074
0.023
T3
2.200
1.601–3.023
< 0.001
3.278
1.982–5.422
< 0.001
T4
2.976
1.208–7.333
0.018
5.687
1.730–18.701
0.004
Lymph nodes status
  
< 0.001
  
< 0.001
Nx
 
Referent
 
Referent
N0
0.367
0.180–0.747
0.006
0.226
0.070–0.733
0.013
N1-N3
0.900
0.434–1.866
0.777
1.384
0.431–4.444
0.585
Grade
  
0.001
  
0.001
G1
 
Referent
 
Referent
G2
1.332
0.961–1.847
0.085
2.367
1.263–4.435
0.007
G3 + G4
2.020
1.402–2.912
< 0.001
3.653
1.849–7.217
< 0.001
Distant metastasis
4.874
3.038–7.818
< 0.001
10.161
5.802–17.794
< 0.001
regional lymph nodes removed
0.940
0.695–1.272
0.690
1.832
1.204–2.790
0.005
Surgery
2.390
1.476–3.870
< 0.001
3.304
1.657–6.590
0.001
LVI
2.078
1.576–2.741
< 0.001
2.741
1.786–4.205
< 0.001
SCCP squamous cell carcinoma of the penis; LVI lymphovascular invasion; CI confidence intervals
Significant values in bold, “-” = no data
The multivariate Cox proportional hazards analyses, for prediction of OS and PCSS in patients with SCCP, who received surgery, was shown in Table 4. The results indicated that the presence of LVI in SCCP was an independent predictor for decreased OS (hazard ratio 1.403, P = 0.039), after adjusting for T stage, grade, lymph nodes status, distant metastasis, regional lymph nodes removed, and surgery. However, LVI was not found to be significantly associated with PCSS (hazard ratio 1.324, P = 0.277). Furthermore, lymph node status (P < 0.001 for both) and distant metastasis (hazard ratio 1.796, P = 0.035; hazard ratio 2.938, P = 0.002) were also significantly independently associated with poor OS and PCSS. T2 stage (hazard ratio 1.405, P = 0.040), T3 stage (hazard ratio 1.528, P = 0.028), G3 + G4 (hazard ratio 1.484, P = 0.049), regional lymph nodes removed (hazard ratio 0.457, P < 0.001) and surgery (hazard ratio 1.768, P = 0.028) were also associated with poor OS according to this model.
Table 4
Multivariate Cox regression analyses predicting overall survival and penis cancer-specific survival
Variables
Overall survival
Penile carcinoma-specific survival
Hazard Ratio
95% CI
P
Hazard Ratio
95% CI
P
T stage
  
0.066
  
0.420
Tx + Ta + T1
1.000
Referent
1.000
Referent
T2
1.405
1.016–1.945
0.040
1.219
0.701–2.118
0.483
T3
1.528
1.046–2.230
0.028
1.302
0.709–2.391
0.395
T4
2.134
0.839–5.428
0.112
2.786
0.797–9.740
0.109
Lymph nodes status
  
< 0.001
  
< 0.001
Nx
1.000
Referent
1.000
Referent
N0
0.522
0.253–1.079
0.079
0.361
0.104–1.247
0.107
N1-N3
1.290
0.596–2.791
0.518
1.645
0.465–5.820
0.440
Grade
  
0.068
  
0.171
G1
1.000
Referent
1.000
Referent
G2
1.057
0.750–1.488
0.752
1.342
0.691–2.607
0.386
G3 + G4
1.484
1.002–2.197
0.049
1.913
0.924–3.959
0.080
Distant metastasis
1.796
1.042–3.095
0.035
2.938
1.484–5.815
0.002
regional lymph nodes removed
0.457
0.314–0.666
< 0.001
0.734
0.424–1.270
0.269
Surgery
1.768
1.063–2.940
0.028
1.992
0.947–4.192
0.069
LVI
1.403
1.017–1.936
0.039
1.324
0.798–2.198
0.277
SCCP squamous cell carcinoma of the penis; LVI lymphovascular invasion; CI confidence intervals
Significant values in bold

Discussion

Although SCCP is a rare disease among men across the globe, it is a significant health problem in most of the developing countries. Owing to rarity, there is a paucity of data to help with clinical decision making regarding the treatment of SCCP. To the best of our knowledge, the present study is first large study including 891 patients with SCCP following surgery. The results of the present study demonstrated that the presence of LVI was the significant independent predictor of decreased OS in patients with SCCP following surgery.
Consistent with previous studies [1, 1618], the present study also revealed that LVI was notably associated with metastases to lymph nodes. This finding supports the hypothesis that lymphatic vessel invasion precedes or occurs concurrently with lymph node metastasis [6]. Moreover, the presence of LVI could significantly reduce OS and PCSS in patients with N0 stage but not in the NI-N3 stage. It indicated that the status of LVI in patients with no clinically evident metastasis was a significant predictor of OS and PCSS. This study also revealed that the presence of LVI increased the risk of distant metastasis. Furthermore, it is well-known that the infiltration of tumor cells into lymphatics or vessels is a crucial step in tumor dissemination. And the presence of LVI was noticeably associated with poor outcome in lymph node-negative patients. As reported by recent studies [19], these findings revealed that LVI might be an important predictor not only of lymphatic but also the hematogenous spread of SCCP. Moreover, LVI was closely associated with T stage and tumor grade. Previous studies reported that 82.7% of the patients with SCCP, with invasive or poorly differentiated tumors, had lymph node metastases [20]. Recent studies also reported that tumor stage and poorly differentiated cancer were independent predictors of lymph node metastases in penile squamous cancer [17]. Thus, the present association study between LVI status and T stage or tumor grade further highlighted the significance of LVI as a predictor of SCCP.
An early study including 145 patients with penile cancer treated in São Paulo, Brazil, reported that lymphatic and venous embolizations were not significantly associated with disease-free and overall survival according to Kaplan-Meier analyses [16]. Conversely, the findings of this study demonstrated that the presence of LVI significantly reduced the OS and PCSS in patients with SCCP in univariate analyses. Moreover, we also determined that the patients with LVI exhibited a lower OS and PCSS than those without LVI for each clinicopathological characteristic (Tx + Ta + T1 stage, N0 stage, grade 1, grade 2, no distant metastasis), suggesting that LVI might play a crucial role in the prognosis of early SCCP.
Using multivariate Cox proportional hazards analyses, the study described a risk classification for men with SCCP. The results demonstrated that the presence of LVI in SCCP was an independent prognostic factor for OS but not for PCSS, after adjusting for T stage, grade, lymph nodes status, distant metastasis, regional lymph nodes removed, and surgery. These findings were similar to those reported by Costa et al. [19], their data showed that LVI was an independent predictor of recurrence-free survival but not of disease-specific survival in patients with penile carcinoma. In contrast, Liu et al. [21] reported that vascular or lymphatic invasion was not significantly associated with overall survival of patients with SCCP. The differences between the results of the present study and those reported by Liu et al. could be attributed to differences in the study population.
Furthermore, the study confirmed that patients who removed regional lymph nodes exhibited lower occurrence of SCCP with LVI than those who did not. Similarly, patients who received radical surgery showed a lower incidence of SCCP with LVI compared to those who did not. These results suggested that patients with positive LVI would be more likely to undergo radical surgery and lymphadenectomy. As reported by Guimarães et al. [22], amputation and regional lymphadenectomy were preferred treatment of choice for invasive penile cancer.
Although this study was carefully conducted, several limitations to this study do exist. First, the study population was only comprised of some patients from the United States. Moreover, this is a retrospective analysis of patients with SCCP, and it is difficult to organize large prospective studies to detect the role of LVI. Another limitation was the fact that our study was based on the covariates of cases recorded in the SEER database as we could not get the medical charts of each patient. Despite these limitations, this study was able to demonstrate the effectiveness of LVI as a crucial prognostic indicator for SCCP. However, further studies are needed to validate these results.

Conclusions

In conclusion, LVI is significantly associated with infaust clinicopathological characteristics. It was also associated with increased risk of advanced T stage, high grade, lymph node metastasis and distant metastasis, and patients with the presence of LVI exhibited a worse OS and PCSS than those without the presence of LVI for each clinicopathological characteristic (Tx + Ta + T1 stage, N0 stage, grade 1, grade 2, no distant metastasis). Moreover, our data suggested that LVI was an independent predictor of decreased OS in patients with SCCP following surgery. Taken together, the results suggested that the LVI status might be a crucial prognostic indicator for overall survival in patients with SCCP following surgery. Besides, these findings may guide in the surveillance of therapeutic modalities for penile cancer.

Acknowledgements

The authors wish to thank the Surveillance, Epidemiology, and End Results (SEER) database.

Funding

This work was supported by Young Medical Talent Program of Jiangsu Province (QNRC2016739), Science and Technology Development Program of Suzhou (SYS201601, SYS2018045).

Availability of data and materials

Not applicable.
For the cohorts, all data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. SEER is supported by the Surveillance Research Program (SRP) in NCI’s Division of Cancer Control and Population Sciences (DCCPS). The institutional review board approval was not required for the SEER program of the National Cancer Institute as it utilizes the de-identified public-use database (http://​www.​uab.​edu/​research/​administration/​offices/​IRB/​FAQs/​Pages/​PublicDatasets.​aspx; http://​research.​fiu.​edu/​documents/​irb/​documents/​approvedDataSets​.​pdf).
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Chaux A, Cubilla AL. Advances in the pathology of penile carcinomas. Hum Pathol. 2012;43:771–89.CrossRef Chaux A, Cubilla AL. Advances in the pathology of penile carcinomas. Hum Pathol. 2012;43:771–89.CrossRef
2.
Zurück zum Zitat Erbersdobler A. Pathologic evaluation and reporting of carcinoma of the penis. Clin Genitourin Canc. 2017;15:192–5.CrossRef Erbersdobler A. Pathologic evaluation and reporting of carcinoma of the penis. Clin Genitourin Canc. 2017;15:192–5.CrossRef
3.
Zurück zum Zitat Christodoulidou M, Sahdev V, Houssein S, Muneer A. Epidemiology of penile cancer. Curr Prob Cancer. 2015;39:126–36.CrossRef Christodoulidou M, Sahdev V, Houssein S, Muneer A. Epidemiology of penile cancer. Curr Prob Cancer. 2015;39:126–36.CrossRef
4.
Zurück zum Zitat Audenet F, Sfakianos JP. Psychosocial impact of penile carcinoma. Transl Androl Urol. 2017;6:874–8.CrossRef Audenet F, Sfakianos JP. Psychosocial impact of penile carcinoma. Transl Androl Urol. 2017;6:874–8.CrossRef
5.
Zurück zum Zitat Hamy A, Lam G, Laas E, Darrigues L, Balezeau T, Guerin J, et al. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. Breast Cancer Res Tr. 2018;169:295–304.CrossRef Hamy A, Lam G, Laas E, Darrigues L, Balezeau T, Guerin J, et al. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. Breast Cancer Res Tr. 2018;169:295–304.CrossRef
6.
Zurück zum Zitat Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010;105:1402–12.CrossRef Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010;105:1402–12.CrossRef
7.
Zurück zum Zitat Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13:471–9.CrossRef Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13:471–9.CrossRef
8.
Zurück zum Zitat Galiabovitch E, Hovens CM, Peters JS, Costello AJ, Battye S, Norden S, et al. Routinely reported ‘equivocal’ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. BJU Int. 2017;119:567–72.CrossRef Galiabovitch E, Hovens CM, Peters JS, Costello AJ, Battye S, Norden S, et al. Routinely reported ‘equivocal’ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. BJU Int. 2017;119:567–72.CrossRef
9.
Zurück zum Zitat Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, et al. Lymphovascular invasion in clear cell renal cell carcinoma—association with disease-free and cancer-specific survival. Urol Oncol- Semin Ori. 2014;32:23–30. Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, et al. Lymphovascular invasion in clear cell renal cell carcinoma—association with disease-free and cancer-specific survival. Urol Oncol- Semin Ori. 2014;32:23–30.
10.
Zurück zum Zitat Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153:526–34.CrossRef Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153:526–34.CrossRef
11.
Zurück zum Zitat Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK. Lymphovascular invasion as a prognostic Indicator in stage I non-small cell lung Cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014;97:965–71.CrossRef Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK. Lymphovascular invasion as a prognostic Indicator in stage I non-small cell lung Cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014;97:965–71.CrossRef
12.
Zurück zum Zitat Winters BR, Mossanen M, Holt SK, Lin DW, Wright JL. Predictors of nodal upstaging in clinical node negative patients with penile carcinoma: a National Cancer Database Analysis. Urology. 2016;96:29–34.CrossRef Winters BR, Mossanen M, Holt SK, Lin DW, Wright JL. Predictors of nodal upstaging in clinical node negative patients with penile carcinoma: a National Cancer Database Analysis. Urology. 2016;96:29–34.CrossRef
13.
Zurück zum Zitat Ornellas AA, Nóbrega BLB, Wei Kin Chin E, Wisnescky A, Da Silva PCB, de Santos Schwindt AB. Prognostic factors in invasive squamous cell carcinoma of the penis: analysis of 196 patients treated at the Brazilian National Cancer Institute. J Urol. 2008;180:1354–9.CrossRef Ornellas AA, Nóbrega BLB, Wei Kin Chin E, Wisnescky A, Da Silva PCB, de Santos Schwindt AB. Prognostic factors in invasive squamous cell carcinoma of the penis: analysis of 196 patients treated at the Brazilian National Cancer Institute. J Urol. 2008;180:1354–9.CrossRef
14.
Zurück zum Zitat Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology. 2009;73:822–7.CrossRef Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology. 2009;73:822–7.CrossRef
15.
Zurück zum Zitat Lucia MS, Miller GJ. Histopathology of malignant lesions of the penis. Urol Clin N Am. 1992;19:227–46. Lucia MS, Miller GJ. Histopathology of malignant lesions of the penis. Urol Clin N Am. 1992;19:227–46.
16.
Zurück zum Zitat Lopes A, Hidalgo GS, Kowalski LP, Torloni H, Rossi BM, Fonseca FP. Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy. J Urol. 1996;156:1637–42.CrossRef Lopes A, Hidalgo GS, Kowalski LP, Torloni H, Rossi BM, Fonseca FP. Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy. J Urol. 1996;156:1637–42.CrossRef
17.
Zurück zum Zitat Slaton JW, Morgenstern N, Levy DA, Santos MJ, Tamboli P, Ro JY, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165:1138–42.CrossRef Slaton JW, Morgenstern N, Levy DA, Santos MJ, Tamboli P, Ro JY, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165:1138–42.CrossRef
18.
Zurück zum Zitat Novara G, Galfano A, De Marco V, Artibani W, Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol. 2007;4:140–6.CrossRef Novara G, Galfano A, De Marco V, Artibani W, Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol. 2007;4:140–6.CrossRef
19.
Zurück zum Zitat Da Costa WH, Rosa De Oliveira RA, Santana TB, Benigno BS, Da Cunha IW, de Cássio Zequi S, et al. Prognostic factors in patients with penile carcinoma and inguinal lymph node metastasis. Int J Urol. 2015;22:669–73.CrossRef Da Costa WH, Rosa De Oliveira RA, Santana TB, Benigno BS, Da Cunha IW, de Cássio Zequi S, et al. Prognostic factors in patients with penile carcinoma and inguinal lymph node metastasis. Int J Urol. 2015;22:669–73.CrossRef
20.
Zurück zum Zitat McDougal WS. Carcinoma of the penis: improved survival by early regional lymphadenectomy based on the histological grade and depth of invasion of the primary lesion. J Urol. 1995;154:1364–6.CrossRef McDougal WS. Carcinoma of the penis: improved survival by early regional lymphadenectomy based on the histological grade and depth of invasion of the primary lesion. J Urol. 1995;154:1364–6.CrossRef
21.
Zurück zum Zitat Liu J, Li Y, Zhang Z, Yao K, Ye Y, Xie D, et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol. 2013;31:1519–24.CrossRef Liu J, Li Y, Zhang Z, Yao K, Ye Y, Xie D, et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol. 2013;31:1519–24.CrossRef
22.
Zurück zum Zitat Guimarães GC, Rocha RM, Zequi SC, Cunha IW, Soares FA. Penile Cancer: epidemiology and treatment. Curr Oncol Rep. 2011;13:231–9.CrossRef Guimarães GC, Rocha RM, Zequi SC, Cunha IW, Soares FA. Penile Cancer: epidemiology and treatment. Curr Oncol Rep. 2011;13:231–9.CrossRef
Metadaten
Titel
Prognostic value of lymphovascular invasion in patients with squamous cell carcinoma of the penis following surgery
verfasst von
Kai Li
Jian Sun
Xuedong Wei
Guang Wu
Fei Wang
Caibin Fan
Hexing Yuan
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2019
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5714-1

Weitere Artikel der Ausgabe 1/2019

BMC Cancer 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.